Yüklüyor......

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents. ABT-869, a novel ATP-competitive receptor tyrosine kinas...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Zhou, Jianbiao, Goh, Boon-Cher, Albert, Daniel H, Chen, Chien-Shing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2009
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2729745/
https://ncbi.nlm.nih.gov/pubmed/19642998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-33
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!